Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation

International Journal of Cancer

Volumn 135, Issue 2, 2014, Pages 264-269

  Ko, Frankie Chi Fat ^a   Ping Yam, Judy Wai ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

DLC1; interacting partner; phosphorylation; tumor suppressor gene

Indexed keywords

CAVEOLIN 1; CYCLIC AMP DEPENDENT PROTEIN KINASE; PROTEIN DLC1; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE D; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TENSIN; UNCLASSIFIED DRUG;

CARCINOGENESIS; COLON CANCER; ENZYME ACTIVITY; EPIGENETICS; FOCAL ADHESION; GENE DELETION; GENE INACTIVATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

DLC1; INTERACTING PARTNER; PHOSPHORYLATION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; GTPASE-ACTIVATING PROTEINS; HUMANS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84900017455     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28505     Document Type: Review

References (47)

1. Yuan BZ, Miller MJ, Keck CL, et al. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998; 58: 2196-9.
2. Lahoz A, Hall A,. DLC1: a significant GAP in the cancer genome. Genes Dev 2008; 22: 1724-30.
3. Wong CM, Lee JM, Ching YP, et al. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 2003; 63: 7646-51.
4. Leung TH, Ching YP, Yam JW, et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA 2005; 102: 15207-12.
5. Kawai K, Kiyota M, Seike J, Deki Y, Yagisawa H. START-, GAP3/DLC3 is a GAP for RhoA and Cdc42 and is localized in focal adhesions regulating cell morphology. Biochem Biophys Res Commun 2007; 364: 783-9.
6. Kawai K, Kitamura SY, Maehira K, et al. START-GAP1/DLC1 is localized in focal adhesions through interaction with the PTB domain of tensin2. Adv Enz Reg 2010; 50: 202-15.
7. Holeiter G, Bischoff A, Braun AC, et al. The RhoGAP protein deleted in liver cancer 3 (DLC3) is essential for adherens junctions integrity. Oncogenesis 2012; 1: e13.
8. Vega FM, Ridley AJ,. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582: 2093-101.
9. Durkin ME, Avner MR, Huh CG, Yuan BZ, Thorgeirsson SS, Popescu NC. DLC-, 1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett 2005; 579: 1191-6.
10. Yau TO, Leung TH, Lam S, et al. deleted in liver cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis. PloS one. 2009; 4: e6566.
11. Liao YC, Lo SH,. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol 2008; 40: 843-7.
12. Wong CM, Yam JW, Ching YP, et al. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 2005; 65: 8861-8.
13. Qian X, Li G, Asmussen HK, et al. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA 2007; 104: 9012-7.
14. Xue W, Krasnitz A, Lucito R, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 2008; 22: 1439-44.
15. Qian X, Durkin ME, Wang D, et al. Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer. Cancer Res 2012; 72: 5900-11.
16. Ko FC, Chan LK, Tung EK, et al. Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. Gastroenterology 2010; 139: 1397-407.
17. Shih YP, Liao YC, Lin Y, et al. DLC1 negatively regulates angiogenesis in a paracrine fashion. Cancer Res 2010; 70: 8270-5.
18. Yang X, Popescu NC, Zimonjic DB,. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Cancer Res 2011; 71: 2916-25.
19. Zhong D, Zhang J, Yang S, et al. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J Cell Sci 2009; 122: 414-24.
20. Li G, Du X, Vass WC, et al. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc Natl Acad Sci USA 2011; 108: 17129-34.
21. Low JS, Tao Q, Ng KM, et al. A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Oncogene 2011; 30: 1923-35.
22. Yuan BZ, Jefferson AM, Millecchia L, et al. Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Exp Cell Res 2007; 313: 3868-80.
23. Chan LK, Ko FC, Sze KM, et al. Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo. PloS One 2011; 6: e25547.
24. Durkin ME, Yuan BZ, Zhou X, et al. DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 2007; 11: 1185-207.
25. Liao YC, Shih YP, Lo SH,. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Res 2008; 68: 7718-22.
26. Yam JW, Ko FC, Chan CY, et al. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res 2006; 66: 8367-72.
27. Liao YC, Si L, deVere White RW, et al. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol 2007; 176: 43-9.
28. Chan LK, Ko FC, Ng IO, et al. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. PLoS One 2009; 4: e5572.
29. Lo SH, Tensin. Int J Biochem Cell Biol 2004; 36: 31-4.
30. Qian X, Li G, Vass WC, et al. The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis. Cancer Cell 2009; 16: 246-58.
31. Martuszewska D, Ljungberg B, Johansson M, et al. Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer. PLoS One 2009; 4: e4350.
32. Yam JW, Ko FC, Chan CY, et al. Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. Hepatology 2006; 44: 881-90.
33. Lo SH, Lo TB,. Cten, a COOH-terminal tensin-like protein with prostate restricted expression, is down-regulated in prostate cancer. Cancer Res 2002; 62: 4217-21.
34. Cao X, Voss C, Zhao B, et al. Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation. Proc Natl Acad Sci USA 2012; 109: 1455-60.
35. Homma Y, Emori Y,. A dual functional signal mediator showing RhoGAP and phospholipase C-delta stimulating activities. EMBO J 1995; 14: 286-91.
36. Healy KD, Hodgson L, Kim TY, et al. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol Carcinogen 2008; 47: 326-37.
37. Yamaga M, Sekimata M, Fujii M, et al. A PLCdelta1-binding protein, p122/RhoGAP, is localized in caveolin-enriched membrane domains and regulates caveolin internalization. Genes Cells 2004; 9: 25-37.
38. Du X, Qian X, Papageorge A, et al. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells. Cancer Res 2012; 72: 4405-16.
39. Yang XY, Guan M, Vigil D, et al. p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene 2009; 28: 1401-9.
40. Erlmann P, Schmid S, Horenkamp FA, et al. DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Mol Biol Cell 2009; 20: 4400-11.
41. Heering J, Erlmann P, Olayioye MA,. Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Exp Cell Res 2009; 315: 2505-14.
42. Scholz RP, Regner J, Theil A, et al. DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. J Cell Sci 2009; 122: 92-102.
43. Tripathi V, Popescu NC, Zimonjic DB,. DLC1 interaction with alpha-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity. Mol Cell Biol 2012; 32: 2145-59.
44. Hers I, Wherlock M, Homma Y, et al. Identification of p122RhoGAP (deleted in liver cancer-1) Serine 322 as a substrate for protein kinase B and ribosomal S6 kinase in insulin-stimulated cells. J Biol Chem 2006; 281: 4762-70.
45. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008; 48: 83-90.
46. Scholz RP, Gustafsson JO, Hoffmann P, et al. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. Exp Cell Res 2010; 317: 496-503.
47. Ko FCF, Chan L-K, Man-Fong Sze K, et al. PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. Nat Commun 2013; 4: 1618.